Applicant, as named in the Orange Book

Genzyme Corp

Next listed expiry: Caprelsa on 8 Aug 2028. 4 products with live protection, 0 without.

Products with listed protection

Drug	Ingredient	NDA	Earliest generic entry	Basis
Caprelsa · 2 strengths vandetanib	vandetanib	022405	8 Aug 2028	patent
Qfitlia · 2 strengths fitusiran sodium	fitusiran sodium	219019	7 Dec 2036	patent, carve-out possible
Cerdelga eliglustat tartrate	eliglustat tartrate	205494	13 Dec 2038	patent, carve-out possible
Wayrilz rilzabrutinib	rilzabrutinib	219685	20 Feb 2041	patent

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.